1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Lyka Labs Limited

Lyka Labs Limited

LYKALABS.NS
Lyka Labs LimitedIN flagNational Stock Exchange of India
69.58
INR
-1.46
- -
2.48BMarket Cap
Lyka Labs Limited
LYKALABS.NS
(National Stock Exchange of India)

Recent

price

69.58

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
64.47
- -
58.91
55.08
77.05
- -
47.65
21.82
22.54
19.47
23.39
63.99
30.69
31.88
38.37
35.98
35.57
Revenue per Share
1.12
- -
-0.33
-3.05
-2.29
- -
-2.56
-6.69
-1.95
-21.25
-4.03
13.59
-4.59
-0.75
2.22
-2.81
-2.78
Basic EPS, GAAP
4.04
- -
-0.76
11.49
9.14
- -
8.16
2.81
7.67
1.48
2.63
25
0.27
-2.26
-3.81
-1.65
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10.5
- -
-10.54
-17.08
-19.37
- -
-19.36
-22.17
-21.93
-42.54
-46.27
-32.68
-36.47
-31.86
-26.17
10
9.88
Book Value per Share
43.86
- -
13.75
-11.42
-12.84
- -
-6.53
1.13
-0.59
-20.54
-22.79
-4.39
8.69
17.09
26.15
23.56
23.29
Tangible Book Value per Share
22
- -
22
22
22
22
22
26
28
28
29
29
29
33
36
36
36
Basic Weighted Avg Shares
1,391
- -
1,271
1,189
1,663
- -
1,050
564
642
555
671
1,836
883
1,051
1,385
1,284
1,284
Sales/Revenue/Turnover
15.76
- -
7.47
1.68
10.59
- -
11.92
-26.3
-14.34
-29.57
16.93
45.66
3.11
2.81
8.06
-9.43
-9.43
Operating Margin (%)
57
- -
117
88
109
- -
103
113
73
80
83
173
141
128
68
85
85
Depreciation Expense
24
- -
-7
-66
-49
- -
-55
-173
-56
-605
-116
390
-132
-25
80
-100
-100
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
35.11
- -
- -
28.69
- -
26.3
Effective Tax Rate (%)
1.73
- -
-0.56
-5.54
-2.98
- -
-5.27
-30.65
-8.64
-109.12
-17.22
21.24
-14.96
-2.37
5.79
-7.81
-7.81
Profit Margin (%)
353
-174
-205
-900
-936
- -
-1,027
-1,181
-497
-304
-208
-472
116
129
208
94
94
Working Capital
1,137
706
672
580
289
- -
349
41
784
1,272
1,509
617
648
431
188
230
230
LT Debt
1,425
756
698
560
466
- -
447
528
458
-151
-251
135
457
683
1,036
908
908
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
39.81
- -
- -
6.1
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
158.91
- -
- -
-18.77
- -
- -
Return on Capital (%)
10.64
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.73
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
132
- -
259
LT Borrowings
183
- -
230
LT Finance Leases
2
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
- -
36
Market Capitalization
3,486
2,748
1,623

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
606
- -
633
Cash, Cash Equivalents & STI
66
- -
69
Accounts Receivable, Net
371
- -
350
Inventories
115
- -
136
Total Current Liabilities
430
- -
539
Payables & Accruals
- -
- -
- -
ST Debt
132
- -
259
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
34.73%
-12.31%
Free Cash Flow
- -
-58.58%
-57.2%
Net Income, GAAP
- -
-259.92%
-225.21%
Sales/Revenue/Turnover
- -
33.03%
-7.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
229
280
326
217
1,051
2025
301
412
338
334
1,385
2026
330
367
307
280
1,284

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.57
-0.16
0.53
- -
-0.75
2025
0.4
0.58
0.75
0.49
2.22
2026
0.25
-0.94
- -
-2.13
-2.81

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
immatics biotechnologies GmbH (IMTXW)
Valneva SE (VLAP.PA)
uniQure N.V. (0EE0.L)
BioAge Labs Inc. (BIOA)
InMed Pharmaceuticals Inc. (IN.TO)
NOMAD Power Solutions, Inc. (NMAD)
Business
Lyka Labs Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India and international markets; its core products include lyophilized injections, liquid injections, dry powder injections, topical preparations such as ointments, creams, lotions, foams, and gels, as well as emollients, topical steroids, antifungal agents, anti-bacterial formulations, acne management products, dermatological formulations, pain killers, anti-aging creams, hair care products, anti-dandruff shampoos, sunscreens, cosmeceuticals, proton pump inhibitors, nutraceuticals, anti-malarials, cephalosporins, bone resorption inhibitors, antibiotics, and corticosteroid hormones, with offerings spanning intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetology, urology, wound care, and anesthesia categories. Incorporated in 1976 and headquartered in Mumbai, India, with manufacturing facilities in Ankleshwar, Gujarat, and an R&D center in Andheri East, Mumbai, the company operates a WHO-GMP and ISO 9001-certified production setup and provides contract manufacturing services along with technical assistance including stability testing and bioequivalence data. Recent developments include the acquisition of Agilis Healthcare Private Limited's animal healthcare business in 2023; the launch of Tofacitinib ointment in fiscal year 2023; the establishment of FertiNova division for gynaecology and assisted reproductive technology in fiscal year 2025; new product launches encompassing lyophilised injections, liquid injections, dry powder injections, and topical ointments, creams, and lotions in 2025; re-appointment of Kunal Gandhi as Managing Director in January 2024; ongoing National Company Law Tribunal proceedings for amalgamation with subsidiary Lyka Exports Limited, with hearings in 2024 and 2025; and redemption of all unlisted 10% cumulative redeemable preference shares in September 2025.